Hemophilia patients are loyal to brand-name clotting factors that have enjoyed market dominance for many years, but a shakeup may be coming in the form of monoclonal antibodies, RNA-based treatments and gene therapies if safety factors and treatment durability don't get in the way.
Shire PLC has the world's largest hemophilia franchise following its acquisition of Baxalta Inc., generating more than twice...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
